Jilin Cayman Pharmaceutical Co., Ltd.

The ibuprofen granules (specification: 200 mg/g) developed by Jilin Kaiman Pharmaceutical Co., Ltd. were used as the test preparation, and the ibuprofen granules (trade name: Brufen®, specification: 200 mg/g) of the licensee Kaken Pharmaceutical Co., Ltd were used as the reference preparation. The pharmacokinetic parameters and relative bioavailability of the two preparations after single administration in the fasting and postprandial states were investigated to evaluate whether the two preparations were bioequivalent. At the same time, the safety and tolerability of the two preparations in healthy humans were evaluated.

Sildenafil citrate tablets (specification: 100 mg) developed by Jilin Kaiman Pharmaceutical Co., Ltd. were used as the test preparation, and Sildenafil citrate tablets (trade name: Viagra®, specification: 100 mg) produced by Pfizer Pharmaceuticals Co., Ltd. were used as the reference preparation. The pharmacokinetic parameters and relative bioavailability of the two preparations after a single dose in the postprandial state were investigated to evaluate whether the two preparations were bioequivalent. At the same time, the safety and tolerability of the two preparations in healthy humans were evaluated.

Sildenafil citrate tablets (specification: 100 mg) developed by Jilin Kaiman Pharmaceutical Co., Ltd. were used as the test preparation, and Sildenafil citrate tablets (trade name: Viagra®, specification: 100 mg) produced by Pfizer Pharmaceuticals Co., Ltd. were used as the reference preparation. The pharmacokinetic parameters and relative bioavailability of the two preparations after single administration in the fasting and postprandial states were investigated to evaluate whether the two preparations were bioequivalent. At the same time, the safety and tolerability of the two preparations in healthy humans were evaluated.